Open access, Immunotherapy Biomarkers – Page 16

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

22 de March de 2024 by

Background
Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20xCD3 bispecific antibody that targets CD20-expressing cells via T-…

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

5 de March de 2024 by

Background
Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or progression rem…